Combining pharmacophore and protein modeling to predict CYP450 inhibitors and substrates.

Publisher Summary This chapter discusses experience in homology modeling of cytochrome P450 (CYPs) 2C8, 2C9, 2C18, and CYP2C19 based on the rabbit CYP2C5 crystal structure. A substrate selectivity analysis for the CYP2C subfamily is also discussed in the chapter and highlights the amino acids responsible for the selectivity. Generation of a three dimension-quantitative structure–activity relationship (QSAR) model for a diverse set of CYP2C9 inhibitors taking into account important parameters, such as mechanism of inhibition and stereochemistry, is described in the chapter. Basic validation of the QSAR models involves cross validation using the “leave one out” (L.O.O.) technique or different percentages of elements of the original training set and trying to predict their biological effect by the model generated with the remaining compounds. This method evaluates the predictive power of the model inside the set defined to build it but it could give an overly optimistic view of the performance of the model.

[1]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[2]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[3]  T. Andersson,et al.  Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. , 2001, Journal of medicinal chemistry.

[4]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[5]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[6]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[7]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[8]  C. Masimirembwa,et al.  Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. , 2001, Molecular pharmacology.

[9]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[10]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[11]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[12]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[13]  T. Poulos.  Modeling of mammalian P450s on basis of P450cam X-ray structure. , 1991, Methods in enzymology.

[14]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.